Mark Saad

Track

Insider profile

Currently holds a position at Axsome Therapeutics Inc

Performance

Overall performance
2.9
Performance over holding periods
2.9
30 days 90 days 120 days
Average return 3% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
5 100% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Independent Director Axsome Therapeutics Inc Dec. 1, 2014 -
Chief Financial Officer Plus Therapeutics Inc June 1, 2004 - Aug. 11, 2014
Mark Saad's trades of Axsome Therapeutics Inc's stock


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-01-02 2025-12-31
PlS Planned sale
52,631 -2.4%
139.01
US$1,087,472 		52,631 -2.4% 139.01 US$1,087,472
2026-01-02 2025-12-31
PlS Planned sale
82,614 -1.2%
72.34
US$81,710 		82,614 -1.2% 72.34 US$81,710
2025-09-05 2025-09-05
PrS Proposed sale
86,463
221.34
US$2,257,584 		86,463 221.34 US$2,257,584
2025-09-05 2025-09-05
PlS Planned sale
9,127 -47.7%
125.07
US$1,141,514 		9,127 -47.7% 125.07 US$1,141,514
2024-09-11 2024-09-11
PrS Proposed sale
11,016
91.31
US$1,005,843 		11,016 91.31 US$1,005,843
2024-09-11 2024-09-11
PlS Planned sale
11,016 -52.4%
91.31
US$1,005,871 		11,016 -52.4% 91.31 US$1,005,871
2021-11-19 2021-11-17
B Purchase
100 +inf%
34.40
US$3,440 		100 +inf% 34.40 US$3,440
2021-11-19 2021-11-17
B Purchase
100 +inf%
34.45
US$3,445 		100 +inf% 34.45 US$3,445
2021-11-19 2021-11-17
B Purchase
100 +inf%
34.40
US$3,440 		100 +inf% 34.40 US$3,440
2021-11-19 2021-11-17
B Purchase
3,000 +42.8%
34.53
US$103,597 		3,000 +42.8% 34.53 US$103,597
2019-05-24 2019-05-23
B Purchase
3,500 +99.9%
22.33
US$78,155 		3,500 +99.9% 22.33 US$78,155